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Abstract
Purpose Cancer patients with bone metastases (BMets) are
predisposed to skeletal complications. Bone-targeted thera-
pies such as denosumab or intravenous bisphosphonates
(IVBs) reduce the risk of these complications. This study
characterized patterns of IVB use in these patients in the
USA.
Methods This was a retrospective, observational study using
the Truven Health MarketScan® Commercial and Medicare
databases (2002–2011). Subjects with ≥1 claims of diagnosis
of breast, lung, or prostate cancer (BC, LC, or PC) and ≥1
claims of BMets diagnosis were included. The date of first
BMet diagnosis claim was the “index date.” Key exclusion
criteria were diagnosis of other primary cancer, receipt of IVB,
or <6 months continuous enrollment pre-index. Cumulative
incidence of treatment initiation, interruption, and discontinu-
ation were estimated. Proportions of IVB claims with chemo-
therapy administered on the same day and with renal moni-
toring within 2 weeks prior were summarized. Multivariate
regressions assessing factors associated with IVB initiation
were conducted.
Results Cumulative incidence of IVB initiation at 12 months
post-index was greatest for BC followed by PC and LC, and it
declined with age in all tumor types, e.g., in BC from 62 % at
age <50 years to 47 % at age ≥75 years. At 12 months, IVB
treatment interruption ranged from 16 % (LC) to 31 % (PC),
with discontinuation ranging from 46 % (BC) to 83 % (LC).
Conclusions IVBs are used more frequently in patients with
BMets secondary to BC than PC or LC. Many patients inter-
rupt or discontinue IVB therapy within 12 months of initiation
potentially impacting effectiveness.
Keywords Intravenous bisphosphonates . Solid tumor . Bone
metastases . Healthcare utilization
Introduction
Bone is the most common site of metastases of many solid
tumors. Patients with bone metastases of solid tumors are at
risk of a variety of skeletal complications including spinal
cord compression, pathological fracture, bone surgery, and
radiotherapy to bone. These complications are collectively
referred to as skeletal-related events (SREs) [1]. Bone metas-
tases and SREs predict short survival in patients with breast
and prostate cancer [2, 3]. Intravenous bisphosphonates
(IVBs) such as zoledronic acid and pamidronate have been
shown to prevent the occurrence of SREs in patients with
bone metastases secondary to solid tumors [4–7]. Prior to
the approval of denosumab in the USA in 2010, the IVBs
have been the prevailing treatment for the prevention of SREs
among patients with solid tumors and bone metastases.
However, information on IVB utilization patterns among
patients with solid tumors and bone metastases is not
available. This information may be useful to identify potential
gaps in treatment that may be addressed to improve patient
outcomes. The objective of this study was to document
IVB practice patterns in patients with bone metastases
of breast, lung, or prostate cancer using the latest data
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available from the Truven Health MarketScan® Commercial
and Medicare databases.
Materials and methods
Study design and data source
This study was a retrospective analysis of administrative claims
data from Truven Health MarketScan® Commercial Claims
and Encounters and Medicare and Coordination of Benefits
Databases from September 1, 2002 through June 30, 2011
(“study period”). These databases contain information on
health insurance claims of employees of large, self-insured
corporations and their dependents, along with a few commer-
cial health plans, and of Medicare eligible persons who are also
covered by self-insured employers. Both databases are fully de-
identified and compliant with the Health Insurance Portability
and Accountability Act of 1996. Accordingly, institutional
review board approval was not necessary.
Patient selection
Study subjects included all persons who had evidence of breast,
lung, or prostate cancer and evidence of bone metastases.
Breast, lung, and prostate cancerswere identified based on either
one or more inpatient facility claims with a primary discharge
diagnosis of female breast cancer (International Classification of
Diseases Version 9 Clinical Modification [ICD-9-CM] 174.xx),
lung cancer (ICD-9-CM162.xx), or prostate cancer (ICD-9-CM
185.xx) or two or more claims on different days not more than
6 months apart with a diagnosis of breast, lung, or prostate
cancer. Bone metastases were identified by one or more
inpatient facility claims with a primary discharge diagnosis of
bone metastases (ICD-9-CM 170.xx or 198.5x) or two or more
outpatient claims on different days not more than 6months apart
with a diagnosis of bonemetastases during the study period. The
date of claims was the service date for outpatient claims, while
for inpatient claims, it was the admission date. For each patient,
the “index date”was defined as the date of the first claim with a
diagnosis of bone metastases. The 6-month period prior to the
index date was designated the “pre-index period”; the period
from the index date to the end of continuous enrollment was
designated the “follow-up period.” Exclusion criteria were as
follows: age less than 18 years as of the index date, male patients
with diagnosis of breast cancer or female patients with diagnosis
of prostate cancer, less than 6 months of continuous enrollment
prior to index date, less than 1 month (30 days) of continuous
enrollment on or after index date, no use of IVBs prior to index
date, no diagnosis for qualifying primary cancer on or prior to
the index date, and diagnosis of primary cancer other than the
qualifying primary cancer (i.e., breast, lung, or prostate cancer)
prior to the index date. The algorithm and specific codes for
identification of primary and secondary malignancies by site are
listed in the Appendix.
Patients meeting the inclusion/exclusion criteria were clas-
sified into three mutually exclusive groups defined by tumor
type (breast, lung, or prostate cancer).
Patient characteristics
For each patient, baseline demographic characteristics were
assessed as of the index date, including calendar year, age,
gender, region, and plan type. Comorbidities were assessed
based on Deyo’s version of the Charlson Comorbidity Index
[8]. Also, claims during the 6-month pre-index period were
Table 1 Selection of study subjects by tumor type
Criteria Breast cancer with bone
metastasis, n (%)
Lung cancer with bone
metastasis, n (%)
Prostate cancer with bone
metastasis, n (%)
Diagnosis of solid tumor prior to bone metastases diagnosis 23,909 (100) 20,609 (100) 14,293 (100)
Exclusions
Age less than 18 years on index date 74 (0.3) 51 (0.2) 21 (0.1)
Breast cancer patients who are male 91 (0.4) NA NA
Prostate cancer patients who are female NA NA 54 (0.4)
Less than 6 months of continuous enrollment prior to index date 7,700 (32.2) 4,655 (22.6) 3,576 (25.0)
Less than 30 days of continuous enrollment during follow-up 711 (3.0) 1,281 (6.2) 370 (2.6)
Received IVBs prior to index date 4,429 (18.5) 1,485 (7.2) 1,766 (12.4)
More than one type of primary cancer prior to index date 1,767 (7.4) 3,860 (18.7) 1,845 (12.9)
Missing information 700 (2.9) 358 (1.7) 451 (3.2)
Total excluded 12,239 (51.2) 9,627 (46.7) 6,697 (46.9)
Remaining 11,670 (48.8) 10,982 (53.3) 7,596 (53.1)
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Table 2 Patient characteristics at baseline by tumor type
Characteristic Breast cancer with bone
metastasis (n =11,670)
Lung cancer with bone
metastasis (n =10,982)
Prostate cancer with bone
metastasis (n =7,596)
Index year, n (%)
2003 633 (5.4) 603 (5.5) 502 (6.6)
2004 887 (7.6) 905 (8.2) 741 (9.8)
2005 1,078 (9.2) 1,069 (9.7) 835 (11.0)
2006 1,198 (10.3) 1,055 (9.6) 688 (9.1)
2007 1,476 (12.6) 1,310 (11.9) 851 (11.2)
2008 1,750 (15.0) 1,683 (15.3) 1,087 (14.3)
2009 2,331 (20.0) 2,108 (19.2) 1,331 (17.5)
2010 1,718 (14.7) 1,638 (14.9) 1,157 (15.2)
2011 (Through June 30) 599 (5.1) 611 (5.6) 404 (5.3)
Age, year, mean (SD) 59.4 (12.7) 64.3 (10.8) 73.4 (10.7)
Males, n (%) NA 6,027 (54.9) 7,596 (100.0)
Region, n (%)
South 4,504 (38.6) 3,850 (35.1) 2,221 (29.2)
North Central 3,308 (28.3) 3,617 (32.9) 2,447 (32.2)
West 2,087 (17.9) 1,653 (15.1) 1,674 (22.0)
Northeast 1,515 (13.0) 1,561 (14.2) 1,088 (14.3)
Unknown 256 (2.2) 301 (2.7) 166 (2.2)
Plan type, n (%)
PPO 6,305 (54.0) 5,463 (49.7) 2,864 (37.7)
Comprehensive 2,049 (17.6) 2,795 (25.5) 2,983 (39.3)
HMO 1,717 (14.7) 1,474 (13.4) 1,157 (15.2)
Other 1,599 (13.7) 1,250 (11.4) 592 (7.8)
Charlson index, mean (SD)a 4.6 (3.2) 5.6 (3.4) 3.4 (2.5)
Additional sites of metastases during pre-index period, n (%)
Lymph nodes 1,641 (14.1) 1,259 (11.5) 251 (3.3)
Respiratory sites 1,466 (12.6) 9,873 (89.9) 183 (2.4)
Liver 1,004 (8.6) 1,111 (10.1) 78 (1.0)
Central nervous system 740 (6.3) 1,778 (16.2) 78 (1.0)
Other sites 1,437 (12.3) 982 (8.9) 460 (6.1)
None 7,300 (62.6) 1,075 (9.8) 6,704 (88.3)
Visits to specialist during pre-index period, n (%)
Oncologist 4,155 (35.6) 3,392 (30.9) 1,258 (16.6)
Urologist NA NA 4,406 (58.0)
Healthcare utilization during pre-index period
Number of physician office visits, mean (SD) 12 (10.4) 15 (12.3) 10 (8.2)
Number of hospital outpatient visits, mean (SD) 6 (7.8) 9 (9.7) 4 (5.8)
Hospitalization, n (%) 2,105 (18.0) 3,808 (34.7) 1,242 (16.4)
Oral bisphosphonate, n (%) 990 (8.5) 436 (4.0) 328 (4.3)
Long-acting opioid, n (%) 978 (8.4) 2,357 (21.5) 512 (6.7)
Short-acting opioid, n (%) 5,859 (50.2) 7,102 (64.7) 3,259 (42.9)
Chemotherapy, n (%) 3,552 (30.4) 4,328 (39.4) 3,452 (45.4)
Systemic corticosteroid, n (%) 3,955 (33.9) 6,333 (57.7) 1,931 (25.4)
Targeted therapy, n (%) 927 (7.9) 932 (8.5) 17 (0.2)
Hormonal therapy during pre-index period, n (%) 3,915 (33.5) 473 (4.3) 4,689 (61.7)
Hypercalcemia 62 (0.5) 45 (0.4) 16 (0.2)
SREs during pre-index period, n (%)
Radiotherapy 98 (0.8) 159 (1.4) 26 (0.3)
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assessed for presence of diagnoses of additional sites of
metastases (lymph nodes, respiratory sites, liver, central
nervous system, and other sites), evidence of visits to
specialist (hematologist, oncologist, and urologist [for
prostate cancer patients]), hospitalizations, receipts of
medications/services for oral bisphosphonates, long-acting
and short-acting opioids, chemotherapy, systemic corticoste-
roids, targeted therapy, hormonal therapy, orchiectomy (for
prostate cancer patients), SREs, hypercalcemia, and number
of physicians’ office visits and hospital outpatient visits. SREs
were identified using algorithms employed in a previously
published study [9].
Outcome measures and analyses
The primary measure of interest was the time from index date
(bone metastases diagnosis) to the first claim for IVB therapy
during follow-up period. Time to first IVB therapy claim was
analyzed by tumor type using cumulative incidence methods
with death as a competing risk [10, 11]. Because information
on mortality was unavailable, the date of disenrollment from a
plan was used as a proxy for death as mortality. Because
patients with metastatic cancer are not likely to otherwise
disenroll from their health plans, disenrollment is likely a
reasonable proxy for mortality [12, 13]. Patients who did not
receive any IVBs during the study period and were enrolled at
the end of the study period were censored.
For patients who received IVBs during follow-up, time to
IVB therapy interruption and IVB therapy discontinuation
were analyzed. Interruption was defined as the time from
IVB therapy initiation to the first occurrence of gap of more
than 60 days without a subsequent IVB claim as IVB admin-
istration is recommended every 3 to 4 weeks. Time to IVB
therapy discontinuation was defined as the time from therapy
initiation to the date of last IVB claim. Time to interruption
and discontinuation were analyzed by tumor type using cu-
mulative incidence methods. For analyses of time to treatment
interruption, therapy discontinuation was defined as a com-
peting risk. For analyses of time to discontinuation, patients
with a last claim for IVBwithin 60 days of the end of the study
were censored.
Among patients who received IVBs during the follow-up
period, each IVB administration was assessed for evidence of
concurrent chemotherapy (IV, oral, or other chemotherapy) on
the same day and for evidence of renal function tests on or
within a 14-day period before the IVB administration. The
number and percentage of IVB administrations with concurrent
chemotherapy or renal function tests were calculated by tumor
type.
The associations between various independent variables
and receipt of IVBs during follow-up were analyzed and
expressed as hazard ratios with 95 % confidence intervals.
Stepwise longitudinal Cox proportional hazards regression
analyses were conducted by tumor type where patient charac-
teristics and time-dependent covariates were selected for entry
into the model based on a P value ≤0.20 and dropped from the
model based on a P value ≥0.10. Time-dependent variables
for SREs (spinal cord compression, pathological fracture,
surgery to bone, and radiotherapy to bone) and hypercalcemia
of malignancy were forced into these models. Other time-
dependent covariates included receipt of long-acting and
short-acting opioids, systemic corticosteroids, chemotherapy,
targeted therapy (i.e., bevacizumab, crizotinib, erlotinib,
gefitinib, lapatinib, and trastuzumab), hormonal therapy, and
orchiectomy procedure. All patient characteristics assessed on
index date and over the pre-index period were also included.
All analyses were conducted using SAS® Proprietary
Software, Release 9.2.3 (SAS Institute Inc., Cary, NC).
Results
Among 23,909 patients with bone metastases and breast cancer
identified in the databases, 11,670 patients (49 %) qualified for
the study. Among 20,609 patients with bone metastases and
lung cancer, 10,982 patients (53 %) qualified for the study.
Among 14,293 patients with bone metastases and prostate
cancer, 7,596 patients (53 %) qualified for the study (Table 1).
Table 2 (continued)
Characteristic Breast cancer with bone
metastasis (n =11,670)
Lung cancer with bone
metastasis (n =10,982)
Prostate cancer with bone
metastasis (n =7,596)
Pathological fracture 567 (4.9) 492 (4.5) 246 (3.2)
Surgery to bone 78 (0.7) 112 (1.0) 31 (0.4)
Spinal cord compression 13 (0.1) 22 (0.2) 3 (0.0)
Duration of follow-up, months, mean (SD) 16.5 (15.4) 7.7 (8.3) 15.5 (14.4)
SRE skeletal-related event; SD standard deviation; PPO preferred provider organization; HMO health maintenance organization
a Calculated over 6 months prior to index date
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The most frequent reason for exclusion was <6 months of
continuous enrollment prior to the index date.
Mean (SD) age was 59.4 (12.7)years, 64.3 (10.8)
years, and 73.4 (10.7)years in the breast, lung, and
prostate cancer cohort, respectively (Table 2). In the lung
cancer cohort, 55 % were male. For all cohorts, the
majority of patients resided in the South or the North






























































































a. IVB therapy initiation since index date (first IVB claim, death as competing risk)
b. IVB therapy interruption (gap of >60 days between IVB claims, discontinuation as competing risk)
c. IVB therapy discontinuation (last IVB claim)
N at risk by tumor type
Breast cancer 6936 2785 1132 445
Lung cancer 3654 388 98 23
Prostate cancer 3294 1105 392 153
N at risk by tumor type
Breast cancer 6936 1585 398 105
Lung cancer 3654 200 31 7
Prostate cancer 3294 549 130 42
N at risk by tumor type
Breast cancer 11670 1964 836 359
Lung cancer 10982 1110 268 89
Prostate cancer 7596 1826 689 278
Fig. 1 Cumulative incidence of
IVB therapy initiation and IVB
therapy interruption and
discontinuation by tumor type: a
IVB therapy initiation since index
date (first IVB claim, death as
competing risk), b IVB therapy
interruption (gap of >60 days
between IVB claims,
discontinuation as competing
risk), c IVB therapy
discontinuation (last IVB claim).
Footnote numbers reported under
each figure are number of patients
at risk at month 0, 12, 24, and 36
reported by tumor type
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organizations (PPOs) or comprehensive plans. Based on
the mean (SD) Charlson index during the pre-index pe-
riod, lung cancer patients had the most comorbidities,
followed by breast and prostate cancer patients. The
mean (SD) duration of follow-up was 16.5 (15.4)months,
7.7 (8.3)months, and 15.5 (14.4)months among the
breast, lung, and prostate cancer cohorts, respectively.
During the follow-up period, among the three tumor types,
breast cancer patients received IVBs most frequently (n =




































































































a. Breast cancer with bone metastasis
b. Lung cancer with bone metastasis
c. Prostate cancer with bone metastasis
N at risk by index age   
< 55 310 83 33 14
55–64 1624 418 138 37
65–74 1773 441 192 97
75+ 3889 884 326 130
N at risk by index age   
< 55 1941 236 55 19
55–64 4235 381 87 23
65–74 2613 276 66 28
75+ 2193 217 60 19
N at risk by index age   
< 55 4261 702 314 141
55–64 4050 639 257 97
65–75 1625 285 135 66
75+ 1734 338 130 55
Fig. 2 Cumulative incidence of
IVB therapy initiation by index
age with death as competing risk:
a breast cancer with bone
metastasis, b lung cancer with
bone metastasis, c . prostate
cancer with bone metastasis
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43 %) and lung cancer patients (n =3,654; 33 %). Cumulative
incidence of IVB initiation 12 months post-index was greatest
among breast cancer patients, 58.5% (95% confidence interval
[CI] 57.6 to 59.4 %), followed by prostate cancer patients,
41.5 % (95 % CI 40.4 to 42.7 %), and lung cancer patients,
34.2 % (95 % CI 33.3 to 35.2 %) (Fig. 1). IVB treatment
interruption at 12 months after IVB initiation was greatest
among prostate cancer patients (30.6 %, 95 % CI 28.9 to
32.2 %), followed by breast cancer patients (29.0 %, 95 % CI
27.9 to 30.3%), and lung cancer patients (15.7%, 95%CI 14.5
to 17.0 %). IVB treatment discontinuation after IVB initiation
at 12 months was greatest among lung cancer patients (83.0 %,
95 % CI 81.6 to 84.3 %), followed by prostate cancer patients
(56.0 %, 95 % CI 54.2 to 57.9 %), and breast cancer patients
(45.8 %, 95 % CI 44.6 to 47.1 %). Cumulative incidence of
IVB therapy initiation at 12 months after bone metastases
diagnosis declined with age in all tumor types (Fig. 2), e.g.,
among breast cancer patients, cumulative incidence at
12 months ranged from 61.6 % at age <55 years to 46.9 % at
age ≥75 years.
There were 78,118 IVB claims identified during follow-up
among 11,670 breast cancer patients with bone metastases.
Similarly, 19,077 and 31,954 IVB claims were identified
among 10,982 lung cancer patients with bone metastases
and among 7,596 prostate cancer patients with bone metasta-
ses, respectively. Among breast cancer patients, IV chemo-
therapy was administered on the same day as IVB for 38 % of
IVB claims (Table 3). The corresponding values for lung and
prostate cancer patients were 54 and 26 % respectively. Renal
monitoring was performed on the same day or within a 2-
week period before IVB administration for 65, 61, and 42 %
of IVB claims among breast, lung, and prostate cancer pa-
tients, respectively.
In the multivariable longitudinal proportional hazard re-
gression analyses predicting receipt of IVBs (Table 4), evi-
dence of SREs and hypercalcemia were associated with great-
er subsequent use of IVBs in general. Among breast cancer
patients, hypercalcemia was associatedwith the greatest use of
IVBs (HR=1.86, 95 % CI 1.49 to 2.32), followed by radio-
therapy (HR=1.34, 95 % CI 1.26 to 1.43), surgery to bone
(HR=1.19, 95 % CI 1.05 to 1.35), and pathological fracture
(HR=1.14, 95 % CI 1.03 to 1.25). Among lung and prostate
cancer patients, estimated HRs for SREs and hypercalcemia
were qualitatively similar. Spinal cord compression was asso-
ciated with lower rates of IVB utilization in breast and lung
cancer patients.
In lung and breast cancer patients, later calendar index year
was generally associated with greater utilization of IVBs. The
exception was index year of 2011, which was associated with
lower utilization, although this finding was not statistically
significant. Visits to hematologists were associated with great-
er use of IVBs in the breast and prostate cancer cohorts, and
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Table 4 Proportional hazard models for receipt of IVB by tumor type








P value Hazard ratio
(95 % CI)
P value Hazard ratio
(95 % CI)
P value
Hypercalcemia (vs. none)b 1.86 (1.49, 2.32) <0.001 1.95 (1.42, 2.68) <0.001 1.47 (0.86, 2.51) 0.162
SREb
Spinal cord compression (vs. none) 0.85 (0.62, 1.15) 0.288 0.92 (0.60, 1.42) 0.700 1.21 (0.72, 2.02) 0.469
Pathological fracture (vs. none) 1.14 (1.03, 1.25) 0.007 1.11 (0.96, 1.27) 0.159 1.14 (0.96, 1.34) 0.131
Surgery to bone (vs. none) 1.19 (1.05, 1.35) 0.007 1.21 (1.00, 1.46) 0.050 1.05 (0.82, 1.35) 0.703
Radiotherapy (vs. none) 1.34 (1.26, 1.43) <0.001 1.06 (0.97, 1.15) 0.218 1.16 (1.06, 1.28) 0.001
Index year (vs. 2003)
2004 1.09 (0.96, 1.25) 0.190 1.16 (0.96, 1.41) 0.128 0.89 (0.75, 1.05) 0.154
2005 1.34 (1.18, 1.53) <0.001 1.23 (1.02, 1.47) 0.030 1.04 (0.89, 1.22) 0.625
2006 1.22 (1.08, 1.39) 0.002 1.33 (1.11, 1.59) 0.002 0.99 (0.84, 1.17) 0.927
2007 1.29 (1.14, 1.46) <0.001 1.25 (1.05, 1.49) 0.013 0.86 (0.73, 1.01) 0.073
2008 1.32 (1.17, 1.49) <0.001 1.24 (1.05, 1.48) 0.013 1.02 (0.87, 1.19) 0.817
2009 1.38 (1.23, 1.56) <0.001 1.25 (1.05, 1.47) 0.011 0.88 (0.75, 1.02) 0.098
2010 1.25 (1.11, 1.42) <0.001 1.24 (1.04, 1.48) 0.015 0.88 (0.75, 1.03) 0.120
2011 (through June 30) 0.87 (0.73, 1.03) 0.104 0.98 (0.79, 1.23) 0.875 0.65 (0.51, 0.82) <0.001
Age at index date (vs. less than 55 years)
55 to 64 1.00 (0.95, 1.06) 0.933 1.01 (0.92, 1.10) 0.897 1.04 (0.88, 1.23) 0.676
65 to 74 0.87 (0.80, 0.94) <0.001 0.92 (0.83, 1.02) 0.125 1.05 (0.89, 1.25) 0.548
≥75 0.71 (0.65, 0.78) <0.001 0.80 (0.71, 0.90) <0.001 0.88 (0.75, 1.05) 0.153
Male (vs. Female) – – – – – –
Region (vs. south)
North Central 0.94 (0.89, 1.00) 0.050 – – 1.01 (0.93, 1.10) 0.801
West 0.84 (0.78, 0.90) <0.001 – – 0.78 (0.70, 0.86) <0.001
Northeast 0.77 (0.71, 0.83) <0.001 – – 0.74 (0.66, 0.83) <0.001
Unknown 0.64 (0.52, 0.78) <0.001 – – 0.90 (0.70, 1.15) 0.399
Plan type (vs. PPO)
Comprehensive 0.92 (0.85, 0.99) 0.029 0.84 (0.77, 0.92) <0.001 0.86 (0.79, 0.94) <0.001
HMO 0.76 (0.70, 0.82) <0.001 0.73 (0.66, 0.82) <0.001 0.68 (0.60, 0.77) <0.001
Other 0.92 (0.86, 0.99) 0.025 0.87 (0.79, 0.97) 0.012 0.89 (0.79, 1.02) 0.091
Charlson index assessed during pre-index period (vs. 2or less)
3 – – – – 1.05 (0.97, 1.15) 0.242
4 to 8 – – – – 0.83 (0.76, 0.92) <0.001
9+ – – – – 0.79 (0.68, 0.93) 0.004
Additional sites of metastases during pre-index period
Lymph nodes (vs. none) – – – – – –
Respiratory sites (vs. none) 0.89 (0.82, 0.97) 0.005 1.22 (1.08, 1.37) 0.001 – –
Liver (vs. none) – – – – – –
Central nervous system (vs. none) 0.68 (0.60, 0.76) <0.001 0.72 (0.65, 0.80) <0.001 – –
Other sites (vs. none) 0.90 (0.83, 0.98) 0.011 0.83 (0.73, 0.94) 0.003 – –
Visits to specialist during pre-index period
Hematologist (vs. none) 1.05 (0.99, 1.12) 0.074 – – 1.30 (1.17, 1.45) <0.001
Oncologist (vs. none) – – – – 1.12 (1.02, 1.23) 0.016
Urologist (vs. none) – – – – 0.93 (0.87, 1.00) 0.065
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in the prostate cancer cohort. Receipt of short-acting opioids,
chemotherapy, systemic corticosteroids, targeted therapies,
and various hormonal therapies were all associated with
higher use of IVBs in all cancer types.
Discussion
This was a retrospective, observational study using health
insurance claims data to document IVBs practice patterns in
patients with bone metastases secondary to breast, prostate, or
lung cancer. To the best of our knowledge, this study is the
first to report such results. The use of IVBs was greatest
among breast cancer patients (59 %), followed by prostate
(43 %) and lung (33 %) cancer patients. For most of the
patients who received IVBs, treatment was initiated within
12 months from the date of diagnosis of bone metastasis. The
reason for the relatively high frequency of utilization of IVBs
among breast cancer patients relative to prostate and especial-
ly lung cancer patients is unknown but may relate to the
perceived relative prognosis of patients. Because breast cancer
patients having the longest expected survival, clinicians may
reason that these patients are most likely to benefit from IVB
treatment.
Interruption of IVB treatment defined as a gap in adminis-
tration of 60 days or more was relatively frequent. At
12 months after IVB therapy initiation, the cumulative inci-
dence of interruption was 29% in breast cancer patients, 31 %
in prostate cancer patients, and 16 % in lung cancer patients.
At 12 months after IVB initiation, it was estimated that 46 %
of breast cancer patients, 56 % of prostate cancer patients, and
83 % of lung cancer patients had discontinued IVB therapy.
Table 4 (continued)








P value Hazard ratio
(95 % CI)
P value Hazard ratio
(95 % CI)
P value
Healthcare utilization during pre-index period
Hospitalization (vs. none) 0.87 (0.81, 0.93) <0.001 0.85 (0.79, 0.91) <0.001 0.87 (0.79, 0.97) 0.011
Oral bisphosphonate (vs. none) – – 1.17 (1.00, 1.37) 0.054 – –
Number of physician office or hospital outpatient visits (vs. 10 or less)
11 to 15 0.99 (0.93, 1.06) 0.858 0.97 (0.88, 1.08) 0.600 – –
16 to 25 0.95 (0.89, 1.01) 0.110 0.89 (0.80, 0.98) 0.021 – –
25+ 0.76 (0.71, 0.83) <0.001 0.73 (0.66, 0.81) <0.001 – –
Receipt of medications and therapiesb
Long-acting opioid (vs. none) – – – – – –
Short-acting opioid (vs. none) 1.06 (1.01, 1.12) 0.030 – – – –
Chemotherapy (vs. none) 1.08 (1.02, 1.16) 0.011 1.46 (1.34, 1.58) <0.001 1.23 (1.11, 1.36) <0.001
Systemic corticosteroid (vs. none) 1.11 (1.05, 1.17) <0.001 1.46 (1.35, 1.59) <0.001 1.16 (1.08, 1.25) <0.001
Targeted therapy (vs. none) 1.34 (1.23, 1.45) <0.001 1.16 (1.06, 1.28) 0.002 1.58 (0.97, 2.57) 0.064
Hormonal therapy
LHRH agonist (vs. none) 1.58 (1.35, 1.83) <0.001 – – 1.58 (1.42, 1.75) <0.001
LHRH antagonist (vs. none) – – – – – –
Anti-androgen (vs. none) – – 3.85 (1.39, 10.62) 0.009 1.36 (1.27, 1.46) <0.001
Orchiectomy (vs. none) – – – – 1.94 (1.53, 2.48) <0.001
Aromatase inhibitor (vs. none) 1.20 (1.14, 1.27) <0.001 – – – –
Estrogen receptor downregulators (vs. none) 1.36 (1.22, 1.52) <0.001 – – – –
Selective estrogen receptor modulators (vs. none) 1.13 (1.05, 1.21) 0.001 – – – –
Other hormonal therapy (vs. none) – – – – – –
SRE skeletal-related event; PPO preferred provider organization; HMO health maintenance organization; LHRH luteinizing hormone-releasing
hormone; CI confidence interval
a Covariates were selected into the model based on p ≤0.20 and dropped when p ≥0.10. SREs and hypercalcemia were forced into the model
b Time-dependent covariates
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The high cumulative incidence of discontinuation and lower
frequency of interruption among lung cancer patients likely
reflects their relatively poor prognosis and survival.
IVB was administered concurrently with IV chemotherapy
in only 26 to 54 % of IVB administrations. This suggests that
the administration of IVBs may be associated with substantial
incremental costs associated with the administration of such
therapy. Also, renal monitoring prior to IVB administration
was not necessarily conducted as recommended in FDA ap-
proved labeling [14], as only 42 to 65 % of IVB administra-
tions were accompanied by renal monitoring on the same day
or within a 2-week period before IVB administration. The
percent of patients receiving renal monitoring on the day of
IVB administration was least for prostate cancer patients.
These patients were also least likely to receive IV chemother-
apy on the day of IVB administration. Further research is
required to understand the reasons and outcomes associated
with poor compliance with recommended renal monitoring
for patients receiving IVBs.
Not surprisingly, patients with SREs were more likely to
receive IVBs. Use of IVBs declined with age. Similar results
with respect to age were reported by Giordano et al. in a study
conducted among breast cancer patients with age 65 or older
[15]. Index year of 2011 was associated with lower IVB
utilization, although this association was not statistically sig-
nificant. This result could be due to incomplete data for year
2011 as the study period ended on June 30, 2011.
Some inherent limitations in health insurance claim data
generally and the Truven databases in particular should be
noted. Health insurance claims data contain information on
diagnosis and procedure codes from health insurance claims.
In the clinical setting, some conditions or procedures may not
be coded and different providers may use different codes for
the same diagnosis or procedure. Codes used in this study for
the identification of breast, prostate, and lung cancer, bone
metastases, and comorbid conditions are consistent with those
used in prior published studies and the previous study of the
utilization of IV bisphosphonates [6]. However, the sensitivity
and specificity of these codes measured against a “gold stan-
dard” of a clinically rich dataset such as a trial dataset or
electronic medical record have not been assessed.
The particular database used in this study is based on a large
convenience sample. Because the sample is not random, it may
contain biases or fail to generalize well to other populations.
Specifically, the data come from mostly large employers. As a
consequence, persons employed in medium and small firms are
not well represented. Also, the database does not include
Medicaid patients so that children and lower income individuals
are not well represented. While Truven databases are geograph-
ically diverse, they are not geographically representative of the
United States population. Although the databases include in-
formation on lab tests received, they do not include lab results,
so it is not possible to characterize patients in terms of clinical
metrics such as prostate specific antigen, lactose dehydroge-
nase, and tumor markers nor is information on cancer staging
available. While the claims’ histories are largely complete for
patients in the commercial database, there may be gaps in the
claims history of Medicare patients when Medicare either pays
100 % (and hence there is no coordination of benefit with the
retiree benefit plan) or denies payment altogether for a claim.
The former situation may occur under part A (i.e., for hospital
claims) when patients hit their deductible typically when they
are admitted multiple times within a defined benefit period
(typically 60 days). So for the sickest patients, some hospital
claims may be missing. This likely had little effect on our
estimates of utilization of IVBs, as these are typically adminis-
tered in the outpatient setting. Also, mortality information was
unavailable and disenrollment information was used as a proxy
for death. Although patients who have metastatic cancer are
presumably unlikely to enroll from their health plans, we were
not able to validate use of disenrollment as a proxy for death in
this population. Lastly, although denosumab was approved for
use in prevention of SREs in patients with bone metastases of
solid tumors in November 2010, the frequency of denosumab
claims was sparse in our databases and therefore analyses of
denosumab utilization were not conducted. Further research
should focus on the effects of the addition of denosumab to
the armamentarium of treatments for bone metastases on the
extent of treatment and outcomes for patients who are candi-
dates for such therapy.
In conclusion, IVBs are used more frequently in patients
with bone metastases secondary to breast cancer than prostate
or lung cancer with many patients interrupting or discontinuing
IVB therapy within 12 months of initiation. Previous claims
data analyses have shown that nonpersistent zoledronic acid
use was associated with higher monthly rates of skeletal com-
plications [16]. These results suggest that there are gaps in
treatment of patients with bone metastases and that outcomes
for these patients might be improved by expanding utilization
of therapies to prevent SREs.
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Table 5 ICD-9-CM diagnosis codes used in the analysis
Cancer site Codes for primary malignancy codes Secondary malignancy codes
Lung 162.xx, 163.xx, 164.0x, 164.2x, 164.3x, and 165.xx 197.0x, 197.1x, 197.2x, and 197.3x
Gastrointestinal 150.xx, 151.xx, 152.xx, 153.xx, 154.xx, 159.0x, and 159.1x 197.4x, 197.5x, 197.6x, and 197.8x
Liver 155.xx 197.7x
Breast 174.xx and 175.xx 198.81
Kidney and urinary tract 188.xx and 189.xx 198.0x and 198.1x
Brain 191.xx and 192.xx 198.3x and 198.4
Adrenal grand 194.xx 198.7x
Reproductive organs 180.xx, 182.xx, 183.xx, and 184.xx 198.82 and 198.6x
Primary cancers were identified based on ICD-9-CM diagnosis codes 140.xx–195.xx, 200.xx–208.xx, except for 171.xx (malignant neoplasm of
connective and other soft tissue), 173.xx (other malignant neoplasm of skin), and 195.xx (malignant neoplasm of other and ill-defined sites)
Support Care Cancer (2014) 22:103–113 113
